Tesamorelin Dosing: Standard Dose, Schedule, and Reconstitution Explained

Tesamorelin is a prescription growth hormone-releasing hormone analog. Older FDA studies used 2 mg injected under the skin once daily, while the current Egrifta SV label lists 1.4 mg once daily after reconstitution. Unit conversions and vial duration depend on the final concentration, so they require clinician or pharmacist guidance [1,2].

What is tesamorelin and what is it approved for?

Tesamorelin is a synthetic growth hormone-releasing hormone, or GHRH, analog. In plain terms, it signals the pituitary gland to release more growth hormone, which can increase insulin-like growth factor 1, also called IGF-1 [1].

Egrifta and Egrifta SV are brand-name tesamorelin products. They are FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; 2 mg was used in older pivotal trials and original Egrifta labeling, while current Egrifta SV labeling uses a different 1.4 mg dose [1,2,3].

Tesamorelin is not FDA-approved for general weight loss, bodybuilding, anti-aging, or cosmetic fat loss. Any use outside HIV-associated lipodystrophy is off-label and should be discussed with a licensed clinician, because benefits, risks, and monitoring needs may differ from the studied population [1].

How tesamorelin works

Tesamorelin binds GHRH receptors in the pituitary gland. This can raise growth hormone and IGF-1, which are involved in fat metabolism and body composition [1,5].

The main studied outcome is visceral adipose tissue, or VAT. VAT is deep abdominal fat around internal organs, not the same as pinchable fat under the skin [3,4].

FDA-approved use vs. off-label use

The FDA-approved indication is narrow: reducing excess abdominal fat in adults with HIV-associated lipodystrophy [1]. The label also says tesamorelin is not indicated for weight-loss management, and its effect on cardiovascular events has not been established [1].

What is the standard tesamorelin dose?

The answer depends on which product and source you mean. Tesamorelin pivotal trials and older Egrifta labeling used 2 mg once daily by subcutaneous injection, while the current Egrifta SV label lists 1.4 mg once daily after reconstitution [1,2,3].

Those numbers describe FDA labeling and study designs, not instructions for you to use. A clinician must decide whether tesamorelin is appropriate, which product or formulation is being used, and what monitoring is needed [1].

The FDA-labeled and FDA-studied doses

How many units is tesamorelin on an insulin syringe?

Insulin syringe units measure volume. On a U-100 insulin syringe, 100 units equals 1 mL, 50 units equals 0.5 mL, and 10 units equals 0.1 mL. That does not tell you the mg amount unless you know the final concentration in mg/mL.

For example, a vial mixed to 2 mg/mL has a different unit-to-mg conversion than a vial mixed to 5 mg/mL. Because a wrong conversion can cause a wrong dose, patients should confirm the exact unit marking with the prescribing clinician or dispensing pharmacy [1,8].

How compounded tesamorelin dosing can differ

Compounded tesamorelin may come in vial strengths that differ from brand-name products. It is prepared for an individual prescription by a compounding pharmacy, often a state-licensed 503A pharmacy, but compounded drugs are not FDA-approved [8,9].

A compounded label should state the total mg in the vial, the diluent volume, the final concentration, storage directions, and beyond-use date. If any of those are unclear, the pharmacy should clarify before use [8,9].

How do you reconstitute a tesamorelin vial?

Reconstitution means adding the supplied or prescribed diluent to powder so it becomes an injectable solution. Tesamorelin reconstitution differs by product, and 2 mg vial questions should be answered only by the product label or the dispensing pharmacy’s instructions [1,8].

The current Egrifta SV label describes reconstitution with sterile water for injection and gives product-specific steps for mixing, withdrawing, and injecting the labeled dose. Compounded products may use different diluent volumes and storage instructions, so the pharmacy label controls [1,8].

Reconstituting a 1 mg vs. 2 mg vial

A 1 mg vial and a 2 mg vial do not automatically produce the same concentration. The concentration depends on both the amount of peptide powder and the amount of liquid added.

This is why “how do I reconstitute a 2 mg vial?” cannot be answered safely without the specific product label or pharmacy instructions. The same 2 mg vial could produce different mg per unit if mixed with different volumes.

Bacteriostatic water vs. sterile water

Sterile water for injection contains sterile water without a preservative. Bacteriostatic water contains a preservative, often benzyl alcohol, and is sometimes used for multi-dose compounded vials [9].

Brand-name Egrifta SV labeling specifies sterile water for injection for that product [1]. Compounded tesamorelin may have different instructions, but compounded products are not FDA-approved, and patients should follow the dispensing pharmacy’s label [8,9].

How long a reconstituted vial lasts

Brand-name and compounded products can have different storage windows. The Egrifta SV label includes product-specific storage and handling instructions after mixing [1].

For compounded tesamorelin, the beyond-use date is assigned by the pharmacy based on formulation, sterility standards, and storage conditions. Do not rely on a generic internet timeline for a sterile injectable product [8,9].

How long will a 5 mg vial last at standard dosing?

A 5 mg vial’s duration depends on the prescribed daily mg amount and whether the product is intended as a multi-dose vial. Mathematically, vial duration equals total mg in the vial divided by mg described per day, but real-world use must also follow the beyond-use date and discard rules [8,9].

For example, study-attributed 2 mg daily dosing would use 4 mg over 2 days and 6 mg over 3 days, so a 5 mg vial would not map neatly to whole days without waste. This is math based on the study dose, not a personal dosing instruction [3].

When and where should tesamorelin be injected?

The product label describes once-daily subcutaneous injection into the abdomen, with rotation of injection sites. Tesamorelin timing and site directions should follow the prescribed product, because label wording and compounded instructions can differ [1,8].

The abdomen is used because tesamorelin is studied as a subcutaneous injection and the approved condition involves excess abdominal fat. Product instructions generally advise avoiding injection into scar tissue, bruises, the navel, or irritated skin [1].

Why bedtime dosing is often discussed

Some tesamorelin materials describe evening or bedtime use because growth hormone release naturally follows daily rhythms. Patients should not change timing without the prescribing clinician’s instructions [1].

Consistency matters in trials and labeling because tesamorelin was studied as daily therapy. Missed doses, timing changes, and storage problems can affect exposure and safety monitoring [1,3].

Fasted vs. fed timing

Food timing instructions vary by source and product instructions. If a prescription label says to separate tesamorelin from food, the dispensing pharmacy can explain the wording [1,8].

Do not add fasting rules based on social media or a peptide forum. Tesamorelin can affect glucose measures, so people with diabetes risk need clinician guidance rather than self-directed timing changes [1,6].

What does a typical tesamorelin cycle look like?

In FDA studies, tesamorelin was studied as daily therapy over 26 weeks, not as a casual short “cycle.” Some clinics discuss cycle-style use off-label, but that approach is not the FDA-approved indication and has less direct evidence [1,3,4].

In the pivotal HIV lipodystrophy trials, VAT changes were assessed at 26 weeks, and extension data evaluated longer exposure and what happened after stopping therapy. Individual results varied, and side effects and lab changes were monitored [3,4,5].

When results typically appear

Clinical trials measured VAT with imaging, not bathroom-scale changes. In adults with HIV-associated abdominal fat, tesamorelin reduced VAT compared with placebo at 26 weeks in pivotal trials; individual results varied [3,4].

Some clinicians may reassess labs or body-composition measures earlier, such as around 8 to 12 weeks, but the strongest trial evidence is not a guarantee of visible change for every person. Side effects, glucose changes, and IGF-1 levels may also guide whether therapy continues [1,6].

What are the side effects and safety considerations?

Tesamorelin can cause side effects even at FDA-labeled doses. Common issues include injection-site reactions, joint pain, limb pain, swelling, muscle aches, tingling, and itching; serious concerns include elevated IGF-1, glucose changes, and hypersensitivity reactions [1,6].

Tesamorelin is contraindicated in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis, and known hypersensitivity to tesamorelin or related ingredients, according to labeling. The label says tesamorelin should be discontinued if pregnancy occurs [1].

Common side effects

• Injection-site redness, itching, pain, irritation, or bruising [1]
• Joint pain, limb pain, muscle pain, or stiffness [1]
• Swelling or fluid retention [1]
• Tingling, numbness, or carpal-tunnel-like symptoms [1]
• Nausea, rash, or itching in some patients [1]

Who should not use tesamorelin

The FDA label lists several groups for whom tesamorelin is contraindicated, including people who are pregnant, have active cancer, have certain pituitary or hypothalamic conditions, or have had hypersensitivity to tesamorelin [1].

People with diabetes or risk factors for diabetes need extra caution. Tesamorelin may affect glucose control, and trials reported changes in HbA1c and diabetes-related measures in some patients [1,6].

Labs your clinician may check

• IGF-1, because tesamorelin increases growth-hormone signaling and may raise IGF-1 [1,6]
• Fasting glucose or HbA1c, especially if diabetes or prediabetes is present [1,6]
• Pregnancy status when relevant, because tesamorelin is contraindicated in pregnancy [1]
• Cancer history and current symptoms, because growth-hormone-axis drugs require caution in malignancy risk [1]
• Injection-site tolerance and allergic symptoms after starting therapy [1]

How do you get tesamorelin legally and safely?

Tesamorelin is prescription-only, so legal access starts with a clinician evaluation. For FDA-approved use, the brand-name pathway is Egrifta or Egrifta SV; compounded tesamorelin may be prescribed in some settings, but it is not FDA-approved [1,8].

A 503A compounding pharmacy prepares medication for an individual patient prescription under state pharmacy oversight and federal compounding rules. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality before marketing [8,9].

If you are considering tesamorelin, choose a licensed clinician and a pharmacy that provides clear labeling, lot tracking, storage instructions, sterile handling standards, and a way to ask questions. Chia is one telehealth option that offers clinician-reviewed access pathways for compounded peptides when medically appropriate.

What peptides stack well with tesamorelin?

Tesamorelin is sometimes discussed with other peptides in clinical and research practice, but combination use is not FDA-approved for general wellness, anti-aging, or cosmetic fat loss. Tesamorelin combinations lack strong combination-specific trial data, so safety monitoring matters [1,10].

Tesamorelin and ipamorelin

Ipamorelin is a growth-hormone secretagogue that acts through ghrelin-related pathways, while tesamorelin is a GHRH analog. Ipamorelin is not FDA-approved for body composition, fat loss, longevity, or anti-aging use [10,11].

The safety caveat is overlap: both may affect growth-hormone and IGF-1 signaling. That can matter for swelling, joint symptoms, glucose control, and cancer-risk screening, so this type of stack requires clinician oversight [1,6].

Tesamorelin and CJC-1295/Ipamorelin

CJC-1295 and ipamorelin combinations are commonly discussed in peptide clinics because they target growth-hormone pulsatility through related but distinct mechanisms. These uses are not FDA-approved for fat loss, longevity, or performance [10,11].

The safety caveat is that combining growth-hormone-axis peptides may raise IGF-1 more than expected. There are no large FDA-reviewed trials proving safety or benefit for this stack in general weight or longevity care [1,6,10].

Tesamorelin and lifestyle or metabolic care

In the approved population, tesamorelin was studied for VAT reduction, not as a replacement for nutrition, activity, sleep, HIV care, or metabolic risk management. Cardiovascular outcome benefit has not been established [1,3].

The safety caveat is that abdominal-fat goals can overlap with diabetes, liver, lipid, or cardiovascular risk. A clinician may need to evaluate those issues directly rather than focusing only on a peptide plan [1,6].

Keep reading

Peptides

Tesamorelin and Ipamorelin: How the Peptide Combo Works

Longevity Peptides

CJC-1295 and Ipamorelin Dosage: What Patients Should Know

Peptides

CJC Peptide (CJC-1295): What It Is, How It Works, and What the Evidence Shows